Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The idea that exercise and physicial fitness may be associated with a reduction in risk of disease progression in men with relatively low-risk prostate cancer is hardly new, but
Filed under: Living with Prostate Cancer, Management, Prevention, Uncategorized | Tagged: activity, exercise, low risk, preventiuon, progression | 5 Comments »
According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®).
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: dutasteride, low risk, Prevention, progression | 5 Comments »
Apparently, earlier this week, Congressmen Runyan and Baca (the co-chairmen of the Congressional Prostate Cancer Task Force) sent a letter to Secretary Sebelius about prostate cancer screening.
Filed under: Uncategorized | 3 Comments »
The issue of whether some urology practices are investing in equipment capable of delivering intensity-modulated radiation therapy (IMRT) with financial motives is back on the front burner again.
Filed under: Uncategorized | Tagged: IMRT, motive, profit, radiation therapy, self-referral | 4 Comments »
Published reports on the safety and efficacy of extreme hypofactionated radiation therapy (stereotactic body radiation therapy or SBRT, a.k.a. CyberKnife radiation therapy) have, to date, come from just a couple of key centers.
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: CyberKnife, outcome, SBRT, stereotactic body radiation therapy | 2 Comments »
According to an article in today’s New England Journal of Medicine, a rare but recurrent mutation in a gene known as HOXB13 (rs138213197) — a gene that is important in prostate development — appears to be responsible for early-onset, familial prostate cancer in some men of European descent.
Filed under: Uncategorized | 2 Comments »
A new article in the Canadian Medical Association Journal has reported on a careful analysis of the published literature underlying current guidelines on the use of repetitive PSA testing to monitor risk for progression in men receiving first-line treatment for localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: guideline, monitoring, PSA, recurrence | 3 Comments »
According to a new study published on line in Prostate Cancer and Prostatic Diseases, 370/425 urologists who responded to a recent survey felt that active surveillance was a reasonable management strategy and about 350/425 actually manage patients by using this approach. But
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: acceptance, active surveillance, opinion, urologist | 19 Comments »
The American Cancer Society (ACS) yesterday released projected data for the incidence and the mortality of prostate cancer for 2012. The bottom line: they are projecting more new cases and significantly fewer deaths than in 2011.
Filed under: Uncategorized | 1 Comment »
The WordPress.com stats helper monkeys prepared a 2011 annual report for this blog. Here’s an excerpt: London Olympic Stadium holds 80,000 people. This blog was viewed about 630,000 times in 2011. If it were competing at London Olympic Stadium, it would take about 8 sold-out events for that many people to see it. Click here [...]
Filed under: Uncategorized | 3 Comments »
It has previously been proposed by some researchers that daily dosing with magnesium oxide (MgO) — alone or as part of an antiflatulent dietary regimen — can be used to reduce prostate motion (in combination with fiducial markers) during external beam radiation therapy for localized prostate cancer.
Filed under: Management, Treatment, Uncategorized | Tagged: antiflatulent, IMRT, magnesium, MgO, motion, oxide, radiation | Leave a Comment »
It appears that research funding of $80 million will again be directed for use to study prostate cancer through the Department of Defense’s Congressionally Directed Medical Research Program (DoD CDMRP) for the financial year 2012. This is a big and important “win” for prostate cancer research during a time of fiscal constraint.
Filed under: Uncategorized | Tagged: CDMRP, research | 3 Comments »
The following article was just published by Ranjana Srivastava, MD, in The New England Journal of Medicine under the title “Dealing with uncertainty in a time of plenty.”
Filed under: Living with Prostate Cancer, Uncategorized | Tagged: communication, doctor, patient | 4 Comments »
From 12:00 noon to 01:00 p.m. on Wednesday, December 7, the Men’s Health Caucus — Prostate Cancer Task Force and the Men’s Health Network will present “Prostate Cancer Screening: Dangerous or Life Saving?” (a lunch briefing about the controversy over screening for prostate cancer) in the Rayburn Building, B-340, on Capitol Hill in Washington, DC.
Filed under: Uncategorized | 24 Comments »
A quick reminder … on December 5 to 7 the National Institutes of Health (NIH) is holding a State-of-the-Science Conference on the role of active surveillance and watchful waiting in the management of men with supposedly localized prostate cancer. It is free and open to the public or it can be monitored by web cast.
Filed under: Uncategorized | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site